Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence

By LabMedica International staff writers
Posted on 16 Nov 2026

Following radical prostatectomy, an estimated 20% to 40% of prostate cancer patients develop biochemical recurrence, marked by rising prostate-specific antigen levels that may indicate cancer recurrence. More...

Clinicians must then determine whether to add hormone therapy to salvage radiation, balancing potential treatment benefits against quality-of-life effects. To help guide these decisions, an artificial intelligence-based test included in clinical guidelines provides risk stratification using pathology images and clinical data.

Artera’s ArteraAI Prostate Test (Post-RP) has been included in the updated National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Prostate Cancer, Version 1.2027. The test is listed as a risk stratification tool for patients with biochemical recurrence following radical prostatectomy. According to Artera, its AI-based tests are the only such risk stratification tools included in the prostate cancer guidelines and are among just two tests recommended across intermediate-risk, high-risk, and biochemical recurrence patient groups.

The test uses multimodal artificial intelligence to analyze digitized surgical pathology images alongside clinical data, without requiring additional tissue. By assessing the risk of disease progression, it aims to help clinicians make more informed treatment decisions for patients considering salvage therapy after radical prostatectomy.

Commercially available since December 2025, ArteraAI Prostate Test (Post-RP) is supported by validation data published in European Urology and first presented at the 2024 American Urological Association Annual Meeting. The findings demonstrated its ability to stratify patients by metastasis risk and identify those more likely to benefit from adding hormone therapy to salvage radiation. The test has also undergone external validation in institutional cohorts from the University of California, San Francisco, and Mayo Clinic.

Artera’s broader diagnostic portfolio includes FDA-authorized software products ArteraAI Prostate, which received De Novo authorization, and ArteraAI Breast, which obtained 510(k) clearance. The company also holds CE marking for its prostate and breast cancer in vitro diagnostic tests and operates a clinical laboratory in Jacksonville, Florida.

“Artera’s technology supports treatment decisions at multiple points in prostate cancer care. The addition of our test within the NCCN Guidelines for use in the post-RP salvage setting reinforces the role of AI-powered insights in helping clinicians make more personalized, evidence-based treatment decisions throughout a patient’s cancer journey,” said Andre Esteva, CEO and co-founder of Artera.

Related Links
Artera


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Connectivity Solution
EKF Link
Gold Member
Automatic Hematology Analyzer
CF9600
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: iStock

AMP 2026 Underscores Molecular Testing’s Role in Precision Medicine for Women’s Health

Advances in molecular diagnostics are creating new opportunities to improve the detection of sexually transmitted infections, identify antibiotic resistance, and assess cancer recurrence risk in women.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.